Good morning. Today, two of my colleagues explain why you're probably overpaying for medicines. We're also covering 2024 fund-raising, Stonehenge and Taylor Swift. —David Leonhardt
Bad medicine
You probably already know some of the reasons prescription drugs are so expensive. Drugmakers charge as much as the market will bear. Health insurers and the government haven't reined in prices. But there's another reason: middlemen known as pharmacy benefit managers, or P.B.M.s. Your employer or a government insurance program like Medicare hires these companies to negotiate a price with drugmakers and to pay pharmacies. P.B.M.s are supposed to save money by haggling favorable terms with those businesses in exchange for sending them large numbers of patients. But in their quest for higher profits, they are quietly driving up prescription drug costs. Your pharmacy benefit manager is often invisible to you unless you're having trouble filling a prescription. (You probably rely on one of the big three: CVS Health's Caremark, Cigna's Express Scripts or UnitedHealth Group's Optum Rx.) We spent the past year trying to understand them. Today, we published a story about these companies, how they affect drug spending and how they amassed so much control with so little transparency. Here's what we learned.
A middlemanEmployers and governments hire P.B.M.s because they need someone to handle the intricacies of paying for prescription drugs. Say your doctor prescribes a drug like Eliquis to prevent you from having a heart attack. She'll send the prescription to your pharmacy, where you'll pick it up. Behind the scenes, your pharmacy benefit manager is handling several tasks. It likely negotiated a price with Eliquis's manufacturer. It helped determine how much you'll have to pay out of pocket for the medicine. And it will pay your pharmacy for dispensing Eliquis to you.
At a number of points along the way, your P.B.M. may be overcharging. It might steer you toward pricier drugs or charge your employer much more for your medicine than the wholesale cost. Added up across more than 200 million Americans, that means big profits for the largest P.B.M.s and higher costs for the system. Consider the case of Kent McKinley, a cancer patient in Oklahoma who gets his health insurance through a program for state employees. His P.B.M., CVS Caremark, charged Oklahoma $120,000 per year more for his cancer drug than his local pharmacist would have charged. "We were getting ripped off," McKinley said. Often, employers don't know they're being overcharged. Many admitted to us that they struggled to understand how the system works. Executives at the big three pharmacy benefit managers told us that they were not to blame for high drug prices. They say that when you consider all the drugs they oversee, they save substantial money for patients and clients. They say their size and scale are essential to counter the drugmakers, which they point to as the real culprits. They also say employers can be stingy in the benefits they offer to workers. New scrutinyIf P.B.M.s charge too much, why haven't competitors with lower prices swooped in to steal their business? The short answer is that these companies have gotten incredibly big, and the system is maddeningly complex.
The biggest three pharmacy benefit managers now process roughly 80 percent of prescriptions in the United States. After two major mergers in 2018, they are all now part of conglomerates that include insurers and pharmacies. This structure allows them to juice their own business — by pushing patients to use their pharmacies, for instance — and to discourage patients and employers from going elsewhere. That gives the conglomerates an enormous competitive advantage. The result is that smaller players can't get a toehold. There are efforts to dislodge the pharmacy benefit managers — notably, the billionaire Mark Cuban created an online pharmacy to take them on. But such efforts have captured only a tiny share of overall prescriptions. Until recently, regulators had generally given P.B.M.s. a pass. That's changing as high drug prices have prompted more scrutiny. The Federal Trade Commission, lawmakers and state attorneys general have suggested that the P.B.M.s. may be abusing their power. "They're seeking to extract from the system without creating any corresponding value for the system," said Dave Yost, the Republican attorney general in Ohio who has sued Express Scripts and Optum Rx over their business practices. "The patients are the ones that are suffering." For more: Read what to do if you're overpaying for prescriptions.
Politics
International
Climate and Weather
Other Big Stories
Opinions
Workers shouldn't have to risk their lives in heat waves. They should have adequate rest, shade and water, Terri Gerstein writes. Here are columns by Michelle Goldberg on abortion and the Comstock Act and Jamelle Bouie on Donald Trump's "lazy authoritarianism." Games for relaxation. Games for concentration. We have them all. For a limited time, save 50% on your first year of a New York Times Games subscription and enjoy new puzzles every day.
Lives Lived: Donald Sutherland was an actor who could both charm and unsettle and played roles in "M*A*S*H," "Ordinary People" and "The Hunger Games." He died at 88. Beer: This is how it tasted 3,000 years ago. Going abroad: See where your dollar is worth more. Big move: These are the best cities for college graduates. Software updates: Welcome to the era of the A.I. smartphone. Viagra for women? Doctors have been prescribing the creams and pills. Modern Love: I was content with monogamy. I shouldn't have been.
M.L.B.: The St. Louis Cardinals beat the San Francisco Giants in Birmingham, Ala., as the league honored Willie Mays and celebrated Rickwood Field's Negro Leagues history. N.B.A.: The Los Angeles Lakers hired JJ Redick, a player-turned-broadcast analyst with no professional coaching experience, as the team's head coach. Soccer: The Copa América began last night with Lionel Messi and Argentina's 2-0 win over Canada. The U.S. men's national team opens on Sunday against Bolivia.
Taylor Swift's concerts are an economic tour de force. European cities are benefiting this summer. This could influence how countries measure inflation and decide whether they should cut interest rates. It can "muddle the picture for central banks heading into these decisions," one expert in London said. More on culture
Make berries and cream, the perfect cap to a summer meal. Find the best cheap sunglasses. Try a hard seltzer. Tackle any clothing stain with this advice. Charm your picnic guests with these chic tumblers. Take our news quiz.
Here is today's Spelling Bee. Yesterday's pangram was excelling. And here are today's Mini Crossword, Wordle, Sudoku, Connections and Strands. Thanks for spending part of your morning with The Times. See you tomorrow. Sign up here to get this newsletter in your inbox. Reach our team at themorning@nytimes.com.
|
-
No hay comentarios:
Publicar un comentario